- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatmentSilvana Borges
Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
Clin Pharmacol Ther 80:61-74. 2006..We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations...
- Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patientsSilvana Borges
Division of Biostatistics Clinical Pharmacology, Indiana University, School of Medicine, 410 W 10th St, HITS 3000, Indianapolis, IN 46202 e mail
J Clin Pharmacol 50:450-8. 2010..However, endoxifen phenotypes still varied substantially, even with incorporation of CYD2D6 genotype and inhibiting factors, suggesting that other, as yet unidentified factors must be involved in tamoxifen activation...
- A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypesLang Li
Division of Biostatistics, Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN
Cancer Inform 9:93-103. 2010..The power and recovery rate of the true partition for the mixture model approach are investigated in statistical simulation studies, where it outperforms another published method...
- Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearanceSilvana Borges
Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Drug Metab Dispos 33:1052-5. 2005..Considering the required sample size and the low correlation with oral clearance, urinary metabolic ratio is not recommended as the primary outcome variable in studies requiring the detection of modest changes in CYP2D6 activity...